You are here

Article Text

Article menu
Download PDFPDF
Cancer genetics
GOLM1: expanding our understanding of melanoma susceptibility

https://doi.org/10.1136/jmg-2023-109348

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Twitter @elliemaas1

    • Contributors EM wrote the paper (80%), edited the manuscript (30%), assembled figures (50%) and analysed the WES data (90%). CW wrote the paper (5%) and edited the manuscript (5%). ED assembled figures (50%). DJS did bioinformatic processing of samples (100%) and edited the manuscript (5%). BBS edited the manuscript (5%). LGA edited the manuscript (5%). MSS edited the manuscript (5%), conceptualised the study (10%) and obtained ethics. RS edited the manuscript (5%), conceptualised the study (10%) and obtained ethics. HPS edited the manuscript (5%). AML wrote the paper (15%), edited the manuscript (35%), conceptualised the study (80%), obtained ethics and analysed the WES data (10%).

    • Funding HPS holds an NHMRC MRFF Next Generation Clinical Researchers Program Practitioner Fellowship (APP1137127). AML currently holds an Australian Skin and Skin Cancer Early Career Research Grant, and held an NHMRC Early Career Fellowship (APP1158111) during this project and is currently supported by a University of Queensland Faculty of Medicine Fellowship. EM and CW are funded by a Research Training Stipend from the Australian Department of Education. Exome sequencing was funded by an Australian Skin and Skin Cancer Research Centre ECF grant (AML and BBS). The participants were originally recruited to the Brisbane Naevus Morphology Study (BNMS), funded by the NHMRC (APP1062935) and Centre of Research Excellence for the Study of Naevi (APP1099021). This work was also made possible by a Metro South Health Research Support Scheme Program Grant (RSS_2021_028). This research was carried out at the Translational Research Institute (TRI), Woolloongabba, Queensland, Australia.

    • Competing interests PS is a shareholder of MoleMap Limited and e-derm consult and undertakes regular teledermatological reporting for both companies. PS is a medical consultant for Canfield Scientific, Blaze Bioscience and MoleMap Australia Limited, and a medical advisor for First Derm.

    • Provenance and peer review Not commissioned; externally peer reviewed.